Here are 1-2 brief analogies for ASP Isotopes (ASPI):

• They are like an industrial gas company such as Linde or Air Products, but instead of common industrial gases, they're developing advanced technology to produce extremely rare, high-value isotopes for critical medical and nuclear applications.
• Think of them as a specialized materials manufacturer like a DuPont or 3M, but intensely focused on using proprietary technology to create specific isotopes for niche, high-tech markets like nuclear medicine and next-generation nuclear reactors.

• Enriched Molybdenum-100 (Mo-100): A medical isotope intended for use in the preparation of nuclear imaging agents.
• Enriched Uranium-235 (U-235): A nuclear fuel component for new generation HALEU-fueled small modular reactors.
• Silicon-28: An isotope with potential application in the quantum computing market.
• Carbon-14: An isotope with potential application in the pharma/agrochem market.

ASP Isotopes (ASPI) is a pre-commercial stage company. As such, it does not currently have established major customers or sales. However, based on the company's stated focus and target markets, it intends to sell its products primarily to other companies and governmental entities in the following categories:

• Radiopharmacies and Medical Industry Companies: These would be the primary customers for enriched Molybdenum-100 (Mo-100), used in the preparation of nuclear imaging agents. This category also includes entities interested in Zinc-68, Ytterbium-176, Zinc-67, Nickel-64, and Xenon-136 for healthcare applications.
• Nuclear Energy Sector Companies: Specifically, developers and operators of new generation HALEU-fueled small modular reactors (SMRs) would be target customers for enriched Uranium-235 (U-235). This category also extends to potential users of Chlorine-37 and Lithium-6.
• Advanced Technology and Research Companies: This includes companies in the quantum computing sector targeting Silicon-28, and pharmaceutical/agro-chemical companies interested in Carbon-14.

Klydon Proprietary Ltd

Paul Mann – Executive Chairman & Chief Executive Officer

Paul Mann co-founded ASP Isotopes in September 2021 and serves as the company's founder, Executive Chairman, and Chief Executive Officer. He took a temporary leave of absence from his CEO duties for health reasons in October 2025, during which Robert Ainscow served as Interim CEO. Mann resumed his role as CEO and Executive Chairman effective January 19, 2026.

Heather Kiessling – Chief Financial Officer

Heather Kiessling was appointed as the Chief Financial Officer of ASP Isotopes Inc. on July 1, 2024. She is a CPA with over 30 years of experience in life science and high-tech companies. Prior to joining ASP Isotopes, she was a Managing Director at Danforth Advisors LLC, a life science consulting firm. Her career also includes finance leadership roles at Cytonome/ST, LLC and AutoImmune Inc., and she began as an auditor at Price Waterhouse. Kiessling holds a BA from the University of California, San Diego, and an MBA from the University of Michigan Graduate School of Business.

Robert Ainscow – Chief Operating Officer

Robert Ainscow co-founded ASP Isotopes in September 2021 and has served as the Chief Operating Officer since the company's inception. He worked alongside Paul Mann for four years and also held the position of Interim Chief Executive Officer from October 2025 until Paul Mann returned to the role in January 2026.

Hendrik Strydom, PhD – Chief Technology Officer

Dr. Hendrik Strydom possesses over 30 years of experience in isotope enrichment. He is a co-developer of the Aerodynamic Separation Process (ASP) technology, which forms the technological backbone of ASP Isotopes. His work in isotope separation began as a scientist at the South African Atomic Energy Corporation (AEC), where he focused on the laser separation of heavy isotopes. In 1993, he co-founded Klydon, an isotope enrichment company based in South Africa.

Gerdus Kemp, MD, PhD – Medical Director, CEO of PET Labs

Dr. Gerdus Kemp founded PET Labs Pharmaceuticals in South Africa and is its Chief Executive Officer. He brings over thirty years of experience in nuclear medicine and radiopharmaceutical production. Dr. Kemp previously served as Medical Director at Klydon and Molybdos. He holds a PhD in Inorganic Chemistry from the University of Johannesburg and is a lecturer in Radiography at the University of Pretoria.

The key risks for ASP Isotopes (ASPI) are:

1. Pre-Commercial Stage and Technological Commercialization Risk: ASP Isotopes is a pre-commercial stage company, meaning its success is entirely dependent on the successful development, scaling, and commercialization of its proprietary Aerodynamic Separation Process (ASP technology). There is a significant risk that the technology may not achieve commercial-scale production efficiently or cost-effectively, or that its isotopes may not meet the required specifications or production targets (e.g., 20 kg/year of 95% enriched Mo-100). This encompasses both technological hurdles and the successful transition from development to profitable commercial operations.

2. Reliance on Exclusive License and Licensor: The company's entire business model is predicated on an exclusive license to the ASP technology from Klydon Proprietary Ltd. Any issues with maintaining this license, the effectiveness of the underlying technology provided by the licensor, or Klydon's ability to fulfill its commitments, such as providing the first commercial-scale Mo-100 enrichment plant, could severely impact ASP Isotopes' operations and viability.

3. Market Adoption and Competition Risk: Even if ASP Isotopes successfully develops and produces its isotopes, the company faces significant challenges in gaining market acceptance and competing in highly specialized target markets. These include nuclear imaging, HALEU-fueled small modular reactors, quantum computing, and pharma/agrochem. These markets may have established players, alternative technologies, or evolving demands, posing a risk that ASP Isotopes' products may not be adopted or may struggle to achieve competitive pricing and market share.

There are two clear emerging threats for ASP Isotopes (ASPI):

1. Emergence of alternative Mo-99 production methods: ASPI's initial focus is on producing enriched Molybdenum-100 (Mo-100) for use in the preparation of nuclear imaging agents, which typically involves irradiating Mo-100 to produce Molybdenum-99 (Mo-99). A clear emerging threat is the development and commercialization of alternative, non-fission-based methods for producing Mo-99, such as accelerator-based technologies. Companies like NorthStar Medical Radioisotopes are actively deploying such methods. If these alternative technologies become widely adopted, cost-effective, and reliable, they could significantly reduce or eliminate the market demand for Mo-100 produced through ASPI's technology, effectively bypassing ASPI's proposed product pathway to a critical medical isotope.
2. Existing and rapidly developing competition in HALEU production: ASPI intends to use its ASP technology to produce enriched Uranium-235 (U-235) for the High-Assay Low-Enriched Uranium (HALEU) market, which is critical for new Small Modular Reactors (SMRs). However, other companies, such as Centrus Energy, have already begun commercial production of HALEU in the U.S. using existing and proven enrichment technologies like gas centrifuges. As ASPI is pre-commercial and its ASP technology for uranium enrichment is not yet scaled for this market, established and emerging competitors already actively producing or scaling HALEU pose a significant threat. These competitors could capture market share and establish supply chains before ASPI can commercialize its U-235 product, making it challenging for ASPI to penetrate this nascent but competitive market.

ASP Isotopes (ASPI) is focused on producing several isotopes for various industries. The addressable markets for its main products are as follows:

• Enriched Molybdenum-100 (Mo-100): The global Molybdenum-100 market size was valued at USD 4.8 billion in 2024 and is projected to grow to USD 8 billion by 2035. This isotope is intended for use in nuclear imaging agents in the medical industry.
• Enriched Uranium-235 (U-235) for High-Assay Low-Enriched Uranium (HALEU): The global High-Assay Low-Enriched Uranium (HALEU) market was valued at USD 14.24 billion in 2025 and is forecast to reach substantial figures by 2033, demonstrating a Compound Annual Growth Rate (CAGR) of 9.25%. HALEU is a specialized nuclear fuel component for small modular reactors (SMRs) and next-generation reactors. The broader global uranium enrichment market is estimated at USD 14.24 billion in 2025 and is expected to reach USD 22.16 billion by 2030.
• Silicon-28: The global quantum computing market, where Silicon-28 has potential application, is projected to grow from USD 1.6 billion in 2025 to USD 7.3 billion by the end of 2030, at a CAGR of 34.6%. Other estimates for the global quantum computing market size include USD 1.41 billion in 2024, projected to reach USD 4.24 billion by 2030.
• Carbon-14: The global Carbon-14 market size was valued at USD 1.2 billion in 2024 and is projected to reach USD 1.77 billion by 2032, growing at a CAGR of 5.0% from 2026 to 2032. Carbon-14 has potential applications in the pharma/agrochem target end market.

ASP Isotopes (ASPI) is poised for future revenue growth over the next 2-3 years, driven by several key initiatives across its isotope production and commercialization efforts:

1. Commercialization and Scaling of Silicon-28: ASP Isotopes has secured multiple contracts for its enriched Silicon-28, with deliveries anticipated to commence in the first half of 2026. These include agreements with a major U.S. semiconductor company, a large global industrial gas company, and another significant U.S. buyer. The company expects commercial revenue from Silicon-28 in 2026. Production is expected to occur at ASPI's Iceland facility, which began construction in 2025 and is projected to be completed by mid-2026. ASP Isotopes is positioned as the sole commercial supplier of enriched Silicon-28, a critical material for quantum computing and advanced semiconductors.

2. Commercial Production of Carbon-14: Revenue from Carbon-14 is projected to begin in the second quarter of 2026. ASP Isotopes has a long-term take-or-pay agreement with a Canadian customer, guaranteeing a minimum of approximately $2.5 million annually, with potential to reach $5 million per year. Feedstock for Carbon-14 production is expected imminently, and the company's plant, which has already been producing Carbon-12, can begin Carbon-14 production once the feedstock arrives.

3. Expansion of Medical Isotope Business: This includes the scaling of Ytterbium-176 production and strategic acquisitions of radiopharmacies. Commercial quantities of Ytterbium-176 are expected to be delivered throughout the first half of 2026, with the company aiming to scale production to approximately 1 kg per year. Additionally, the acquisition of an independent radiopharmacy in Florida is expected to be accretive to 2026 revenues, EBITDA, and EPS, expanding PET Labs' nuclear medicine operations in the United States.

4. Advancement and Market Entry in Uranium-235 (HALEU) Production: ASP Isotopes' subsidiary, Quantum Leap Energy (QLE), which the company intends to spin off as a separate entity in the first half of 2026, is making progress in the high-assay low-enriched uranium (HALEU) market. QLE has signed a non-binding Memorandum of Understanding with a major U.S. energy company to explore developing facilities for HALEU production in the U.S., a move that aligns with efforts to secure domestic nuclear fuel supply ahead of the anticipated 2028 ban on Russian uranium imports. QLE also has agreements with TerraPower for HALEU supply, with a 10-year supply agreement starting in 2028. Initial pilot results for its Quantum Enrichment technology in early 2026 are crucial for this segment.

5. Consistent Revenue from Molybdenum-100: ASP Isotopes holds a 25-year supply agreement with BRICEM for highly enriched Molybdenum-100, valued at up to $27 million per annum. Deliveries under this contract were scheduled to begin in July 2023. This long-term agreement is expected to provide a steady and significant revenue stream as the company scales its production capacity for this medical isotope.

Share Issuance

• ASP Isotopes completed a follow-on equity offering in October 2025, raising approximately US$210.3 million through the sale of 17,167,380 shares of common stock.
• In July 2025, the company priced an underwritten registered direct offering of 7,500,000 shares at $8.00 per share, expected to generate approximately $60.0 million in gross proceeds.
• ASP Isotopes issued 1,294,778 new shares of common stock in May 2025 following the exercise of warrants, providing approximately $4.9 million in gross proceeds.

Inbound Investments

• ASP Isotopes gained access to a significant indirect line of credit of potentially USD 750 million, primarily through the US Development Finance Corporation, related to the acquisition of Renergen for helium production, with any surplus earmarked for uranium initiatives.
• Its subsidiary, Quantum Leap Energy LLC, has issued convertible notes in private placements to fund the development of laser enrichment production facilities.

Outbound Investments

• ASP Isotopes is in the process of acquiring Renergen Limited, a helium and liquefied natural gas producer with operations in South Africa, which, upon completion, will become a wholly-owned subsidiary.
• The company has acquired a US radiopharmacy to expand its radiopharmaceutical operations.
• ASP Isotopes acquired assets from One 30 Seven Inc. to develop Creber Units for processing water-soluble nuclear waste.

Capital Expenditures

• Capital expenditures for the nine months preceding Q3 2025 amounted to $7.2 million.
• Planned annual outflows for capital investment are projected to be north of USD 75 million, including expansion into Iceland and further investment in South African facilities.
• The primary focus of capital expenditures includes the commissioning and expansion of C-14, Si-28, and Yb-176 enrichment facilities in Pretoria, South Africa, with commercial supply expected during 2025.